Tresiba

Tresiba

insulin degludec

Manufacturer:

Novo Nordisk

Distributor:

Firma Chun Cheong
/
DKSH
Concise Prescribing Info
Contents
Insulin degludec
Indications/Uses
Improve glycemic control in DM patients ≥1 yr.
Dosage/Direction for Use
SC Insulin naïve patient Type 1 DM Recommended starting dose: Approx ⅓-½ of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as a short-acting insulin & divided between each daily meal. Type 2 DM Recommended starting dose: 10 u once daily. Adult patient already on insulin therapy Start at the same unit dose as the total daily long or intermediate-acting insulin unit dose. Ped patient ≥1 yr already on insulin therapy Start at 80% of the total daily long or intermediate-acting insulin unit dose.
Contraindications
Hypersensitivity. During episodes of hypoglycemia.
Special Precautions
Not recommended for the treatment of diabetic ketoacidosis. Risk of hypoglycemia w/ increased intensity of glycemic control, changes in meal pattern, changes in level of physical activity, or changes to co-administered medication. Patients w/ renal or hepatic impairment may be at higher risk of hypoglycemia. Monitor K levels in patients at risk for hypokalemia. Hyperglycemia or hypoglycemia w/ changes in insulin, manufacturer, type, or method of administration. Discontinue if hypersensitivity reactions occur. Use w/ caution in patients w/ visual impairment that may rely on audible clicks to dial the dose. Fluid retention & CHF w/ concomitant use of thiazolidinediones. May impair ability to drive & use machines. Pregnancy & lactation.
Adverse Reactions
Hypoglycemia. Nasopharyngitis, upper resp tract infection, headache. Type 1 DM: Sinusitis, gastroenteritis. Type 2 DM: Diarrhea.
Drug Interactions
Increased risk of hypoglycemia w/ antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (eg, octreotide), & sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Decreased blood glucose lowering effect w/ atypical antipsychotics (eg, olanzapine & clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, OCs, phenothiazines, progestogens (eg, in OCs), PIs, somatropin, sympathomimetic agents (eg, albuterol, epinephrine, terbutaline), & thyroid hormones. Possible increased or decreased blood glucose lowering effect w/ alcohol, β-blockers, clonidine, & lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Blunted signs & symptoms of hypoglycemia w/ β-blockers, clonidine, guanethidine, & reserpine.
MIMS Class
Insulin Preparations
ATC Classification
A10AE06 - insulin degludec ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Presentation/Packing
Form
Tresiba FlexTouch (pre-filled pen) 100 U/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in